Please enter your details to request more information

Image

10.3X Target Returns (Inc HMRC EIS relief)

Invest in the early stage breast and prostate cancer detection that is transforming cancer care.

Request information

Management team and medical advisory board, with unmatched levels of expertise inn key fields.

Image
  • £24.8m Conservative Growth Profit Forecast - 2029.
  • £3.36m Conservative Growth Profit Forecast - 2026.
  • The global breast cancer diagnostics market was valued at USD 4.49 billion in 2023 and is expected to reach over USD 9.00 billion by 2033, poised to grow at a noteworthy CAGR of 7.2% from 2024 to 2033.
  • With Ai-driven tools and genomic insights, we’re shifting from reactive to proactive cancer care, improving survival rates and patient quality of life, through early detection and precision medicine.
  • 1 in 8 women will develop breast cancer in their lifetime.*

‘ By quantifying circulating tumour cells (CTCs), we can identify early tumour activity in patients. The quantification of CTCs allows us to predict the effectiveness of a chemotherapeutic agent in percentage terms before it is even administered. That means we know how many cells will be killed in each round of therapy. We are developing a new platform-based solution to CTC cell counting for routine medical diagnostics. ’

Dr. Martin Burow CEO, The former Head of Asia Pacific for Thermo Fisher

EIS TAX Benefits for Investors

  • 30% Income Tax Relief.
  • 0% Capital Gains Tax.
  • IHT Tax Exempt.
  • Tax Loss Relief.
  • CGT Deferral Relief.
Image
Request information

** https://amp.cancer.org

To be able to deal with your enquiry effectively we will need to contact you via telephone and/or email. By enquiring you consent to being contacted and you consent to your data being stored in accordance with European GDPR regulations. Privacy Policy


Disclaimer: Any person accessing this website or page and considering potential investment opportunities featured here, should make their own commercial assessment of an investment opportunity after seeking the advice of an appropriately authorised or regulated financial advisor. This website or page should not be construed as advice or a personal recommendation to any prospective investor. Investments of this nature carry risks to your capital and can go up or down. Past performance is not indicative of future results. Suitable appropriately qualified investors, sophisticated and high net worth investors only.